Sequence-specific DNA ligands that antagonize DNA-protein interactions represent a potentially powerful means of modulating gene expression. Calicheamicin -il, a member of the DNA-cleaving enedlyne class of anticancer antibiotics, binds to specific DNA sequences through an aryltetrasaccharide domain. To take advantage of this unique sequence-specific recognition capability, the methyl glycoside of the aryltetrasaccharide of caliche min yi (CLM-MG) was used to investigate the ability of glycoconjugate DNA ligands to inhibit DNA-protein interactions. CLM-MG inhibits the formation of DNA-protein complexes at micromolar concentrations in a sequence-specific manner and rapidly dissociates preformed complexes. CLM-MG also inhibits transcription in vivo with similar sequence specificity. These results suggest a strategy for the development of a class of novel biological probes and therapeutic agents.
The ordered regulation of gene expression underlying specific developmental programs or cellular responses to physiologic stimuli relies on sequence-specific DNA-protein interactions (1) . This requisite DNA sequence specificity suggests a means to control cellular responses through the use of DNA ligands that interfere with these specific DNA-protein interactions. To be biologically useful such ligands would need to (i) bind DNA with a high degree of sequence specificity, (ii) antagonize DNA-protein interactions either by inhibition of DNA-protein complex formation or by displacement of preformed complexes, and (iii) exhibit sufficient hydrophobicity to pass through cell membranes and thereby function in vivo. Several types of DNA ligands have been shown to satisfy some of these criteria, including oligodeoxynucleotides involved in triple-helix formation (2, 3) , peptide nucleic acids (4) , and nonintercalating minor groove DNA ligands such as netropsin and distamycin A (5) . However, none of these adequately satisfy all the requirements for specific and biologically useful transcriptional antagonists.
The enediyne compound calicheamicin 'yI (CLM; Fig.   1A ), representative of a class of enediyne glycoconjugate DNA ligands, binds to and cleaves DNA at specific 4-bp sequences. Double-strand DNA cleavage occurs through bioreduction of the trisulfide and subsequent 1,4-benzenoid diradical formation, which results in hydrogen abstraction from adjacent nucleotide bases (10) (11) (12) (13) . Affinity cleavage experiments (7, 8) demonstrate that CLM preferentially cleaves DNA at cytosine-containing homopyrimidine tracts, preferentially TCCT. Comparisons of the DNA cleavage specificity of CLM derivatives indicate that the aryltetrasaccharide domain is largely responsible for sequence-specific DNA binding (8, (14) (15) (16) (17) (18) MATERIALS AND METHODS Preparation of Nuclear Extracts and DNA-Bhin Assays. Nuclear extracts were prepared as previously described (19) from TAg Jurkat cells (20) (24), Oct-i (25) and Oct-i-associated protein (OAP) (26) , NFKB (27) , HNF-1 (28) , and Spl (29) was measured by electrophoretic mobility-shift assay. These protein complexes are representative members of several distinct classes of transcription factors, including the basicleucine zipper or bZIP class (AP1), the rel/dorsal class (NF-icB), the homeodomain class that contains a helix-turnhelix motif (HNF1, Oct-i), and the zinc finger class (Spl). (CLM) and synthesis and structure of the methyl glycoside derivative of the aryltetrasaccharide moiety of CLM (CLM-MG). The schematic of the synthesis of CLM-MG shows the precursor constituents, labeled A-E, and the sequence of steps leading to the product. The strategy for the synthesis of CLM-MG has been previously described in detail (6) . Me, methyl group; Et, ethyl group; Ac, acetyl group; PMB, para-methoxybenzyl protecting group; Phth, phthalimide group. (B) Hypothetical model of CLM-MG (thick lines) bound to an AGGA site of B-form DNA. The model was initially based upon affinity cleavage experiments with CLM (7, 8) and is supported by more recent experiments involving atom transfer between a labeled oligonucleotide and CLM (9).
Predicted CLM-MG binding sites are present within four of the six DNA sequences to which these transcription factors bind ( Fig. 2A) . Among these DNA sequences, the presumably preferred CLM-MG binding site TCCT is present only in the NFAT recognition sequence.
The addition of CLM-MG to DNA-protein binding reactions resulted in the complete inhibition ofNFAT complex formation at concentrations >30 ,uM CLM-MG, with half-maximal inhibition occurring at approximately 5 MM CLM-MG. In contrast, there was no significant inhibition of AP1 or Spl complex formation at concentrations of CLM-MG that signficantly inhibited NFAT-DNA complex formation and minil inhibition at concentrations as high as 100 pM ( Fig. 2B and 2C ). The formation ofDNA-protein complexes involving NF-KB, Oct-i, OAP, and HNF-1 was also inhibited by CLM-MG, although to a much lesser extent than formation ofthe NFAT complex (Fig.  2B) . These results indicate that CLM-MG is capable of inhibiting DNA-protein complex formation in vitro and are consistent with the results predicted on the basis of presence or absence of CLM-binding sites within the transcription factor recognition sequences ( Fig. 2A) .
CLM-MG Rapidly Dissociates Preformed DNA-Protein Complexes. CLM-MG rapidly dissociated preformed NFAT-DNA complexes, with >80%6 inhibition of NFAT-DNA complex formation observed within 1 min of the addition of 100 AM CLM-MG (Fig. 3) . In contrast, addition of excess unlabeled DNA probe resulted in no significant dissociation ofthe DNA-protein complex within 1 min (Fig. 3A, lane 7) . This rapid dissociation of preformed DNA-protein complexes by CLM-MG indicates that sensitivity to inhibition by CLM-MG is not dependent on differences in DNA-protein complex dissociation rates. In addition, the similarity between the rate of dissociation of preformed NFAT-DNA induced by CLM-MG at room temperature and the apparent rate at 4°C ( Fig. 3B) is consistent with the rate constant for the association of CLM-MG and DNA being diffusion limited.
CLM-MG Inhibits Formation of DNA-Protein Complexes with DNA Sequence Specificity. To provide further evidence that the inhibition of DNA-protein complex formation by CLM-MG is sequence specific, alterations were made in the putative CLM-MG-binding sites within the NFAT recognition sequence (Fig. 4A) . Dissociation of preformed DNAprotein complexes was measured after incubation with CLM-MG for 1 min to minimize differences in the dissociation rates of NFAT with the altered sequences. Substitution ofthymidine for guanosine in the first guanosine dinucleotide resulted in decreased sensitivity of the NFAT complex to inhibition by CLM-MG (Fig. 4) . Alterations in the second guanosine dinucleotide eliminated NFAT binding (data not shown), consistent with the identification of these nucleotides as contact sites by methylation interference studies (J. P. Shaw and G.R.C., unpublished data). The presence of overlapping CLM-MG-binding sites within the NFAT recognition sequence gives rise to the prediction that increasing the distance between these sites may increase sensitivity to CLM-MG, since overlapping sites may result in decreased occupation of the site more directly involved in protein contacts. Comparison between the wild-type NFAT recognition sequence and an altered sequence containing an inserted adenosine nucleotide shows that binding of NEAT to the latter sequence is more sensitive to inhibition by CLM-MG (Fig. 4) . Addition of excess unlabeled DNA probe for 1 minute (Fig. 4A, lane 5) resulted in less than 10%o dissociation of the DNA-protein complex for each of the DNA sequences, indicating that the differential inhibition by CLM-MG is not simply a function of differences in the rate of dissociation of NFAT for the different DNA-binding sequence. Thus, the extent to which NFAT-DNA complex formation is inhibited by CLM-MG is dependent on the presence of CLM-MG-binding sites, providing further evidence that CLM-MG functions to inhibit DNA-protein interaction by binding to DNA in a sequence-specific manner.
CLM release of AP1 from composite DNA-binding complexes containing AP1 that bind to sequences containing a CLM-MG recognition site, such as the NFAT complex. The NFKB-IL2 and HNF1-ML2 promoters were also inhibited, although significantly less than inhibition of the NFAT-EL2 promoter (Fig. 5) .
CLM The antiproliferative and toxic effects of CLM-MG are not unexpected and likely result from specific DNA binding and concomitant inhibition of gene expression, given that the sequence specificity is limited to 4-bp sequences.
DISCUSSION
Transcription factors typically form interactions with DNA along the major groove (1). CLM, in contrast, appears to occupy the minor groove (19) . Assuming the DNA-protein interactions that are sensitive to inhibition by CLM-MG depend primarily on major groove contacts, the rapid dissociation of preformed DNA-protein complexes by CLM-MG (Fig. 3 ) is unlikely to result from direct competition for a shared binding site. Rather, CLM-MG binding in the minor This hypothetical binding interaction contrasts with that of the minor groove ligand netropsin, which binds triple-helix DNA without displacing the major groove-bound third strand (32), or 1-methylimidazole-2-carboxamide netropsin, which can bind simultaneously with the major groove-binding protein GCN4(226-281) at a common binding site (33) . However, distamycin, an amide pyrrole minor groove ligand like netropsin, is capable of inhibiting DNA-protein interactions (34, 35) and dissociating preformed DNA-protein complexes (36) . Furthermore, evidence for DNA conformational changes induced by distamycin is provided by direct structural studies of distamycin-DNA complexes (37, 38) . Thus, targeting the minor groove, which appears to be accessible to small ligands in the presence of protein interacting along the major groove, may be a useful strategy in the design of DNA-binding ligands.
The preferential inhibition of NFAT-directed reporter gene expression (Fig. 5) reflects in vivo the same specificity of inhibition of DNA-protein complex formation by CLM-MG that was observed in vitro ( Fig. 2 ) and is consistent with CLM-MG inhibiting gene expression in vivo by inhibiting protein-DNA complex formation in a sequence-specific manner. These results indicate that CLM-MG exhibits many of the properties required for biologically useful, sequencespecific transcriptional antagonists. Unlike many other DNA ligands, the lipophilic nature of CLM-MG, in addition to favoring a minor groove interaction, allows for diffusion of the ligand through cell membranes, thereby permitting direct in vivo targeting of DNA-protein interactions. Furthermore, the sequence specificity and the inherent conformational rigidity of CLM-MG provide a means to specifically target and inhibit DNA-protein interactions. Greater sequence specificity in DNA-carbohydrate interactions should result from recent advances in carbohydrate chemistry permitting extended solid-phase polysaccharide synthesis (39) combined with DNA site-selection techniques. Thus, CLM-MG and other glycoconjugate DNA ligands may serve as lead compounds in the development of novel DNA-targeted therapeutic agents and biologic probes, perhaps ultimately leading to biologically useful DNA ligands.
